DALLAS--(BUSINESS WIRE)-- <\/p>\n
Dallas-based TopMDTM Skin Care today announced results of its first peer-reviewed journal article testing the efficacy of their flagship product, CLn BodyWash for easing symptoms of eczema. The clinical study results appear in the May\/June 2013 issue of Pediatric Dermatology. <\/p>\n
The article, A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis, reports impressive findings seen after consistent use of the product by 18 pediatric patients with eczema. <\/p>\n
Eczema is a chronic, inflammatory skin condition marked by red, itchy rashes affecting millions of Americans, including a disproportionate number of children, and can have a significant impact on quality of life. <\/p>\n
Im extremely pleased that study participants saw such a marked improvement, said Dr. Caitriona Ryan, who was the lead author of the study. There are few effective non-antibiotic, non-steroidal treatment options for families dealing with eczema, and this product gives them an alternative to the commonly prescribed bleach bath, filling an important gap in the market. <\/p>\n
CLn BodyWash is a gentle, non-drying wash designed to cleanse skin prone to eczema, acne, infection and folliculitis. Texas cardiologist Dr. Azam Anwar created the product after his own experience with cellulitis. After realizing there were few effective treatments, he teamed up with friend and renowned dermatopathologist, Dr. Clay Cockerell. Their over-the-counter skincare solution, CLn BodyWash, has the benefits of a bleach bath, but the convenience and portability of a gel cleanser. <\/p>\n
About the Clinical Study <\/p>\n
Ryan, a dermatology resident at Baylor University Medical Center in Dallas, tracked 18 children ages 2 to 11 years with moderate to severe eczema over the past 18 months. Patients were instructed to wash with CLn BodyWash three days per week for the 12-week feasibility study while maintaining their prescribed topical and systemic treatments. Treatment response was measured using an Investigator Global Assessment (IGA) score and the percentage of body surface area (BSA) affected by eczema. <\/p>\n
Dr. Ryan and her colleagues found a statistically significant reduction in the IGA score throughout the study, and the mean reduction in BSA affected from baseline to final measure in all patients was 14.8 percent. <\/p>\n
Parents of children who participated in the study were enthusiastic about the success of CLn BodyWash in treating atopic dermatitis. Based on a questionnaire fielded at the conclusion of the study, when asked if they would recommend the product to friends or family (1 being no way; 10 being definitely), the mean response was 9.25 -- further validating excellent acceptability and tolerability to the sodium hypochlorite-based body wash. <\/p>\n
<\/p>\n
Read the original: DALLAS--(BUSINESS WIRE)-- Dallas-based TopMDTM Skin Care today announced results of its first peer-reviewed journal article testing the efficacy of their flagship product, CLn BodyWash for easing symptoms of eczema. The clinical study results appear in the May\/June 2013 issue of Pediatric Dermatology. The article, A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis, reports impressive findings seen after consistent use of the product by 18 pediatric patients with eczema Continue reading
\nPeer-Reviewed Article Shows CLn\u00ae BodyWash an Effective Solution for Children with Eczema<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"